David Steensma: Terrific Pam Ting described huge body of work identifying WIZ TF as HbF regulator and degrading it

David Steensma, Chief Medical Officer at Ajax Therapeutics, made the following post on Twitter:

“When I was discussing joining Novartis Science as heme head in late 2020, Jay Bradner said, ‘There’s a program I can’t tell you about unless you join us, which is so cool. It will floor you with its potential to help patients, in the fullness of time.’

After I started & could see the data, I agreed with Jay: ‘This is an incredible story – surefire The American Society of Hematology (ASH) Plenary whenever it can be disclosed.’

Today was that day! Terrific Pam Ting described huge body of work identifying WIZ TF as HbF regulator & degrading it.

We don’t know what this approach will do in the clinic. But as Pam said today, there’s potential to improve on limitations of hydroxyurea – higher Hb F, no need for monitoring, less toxicity. I look forward to seeing how this story develops, now from afar. Congrats!!”

Source: David Steensma/Twitter